Aim: to estimate the cost-effectiveness of In the base-case analysis, the to detect 1,000 Age-specific prevalences (Rours et al Chlamydia trachomatis screening during pregnant women with chlamydia were estimated at were 13.5% in women 2016) study pregnancy. Prevention of adverse health outcomes <21 years (n=251), 6.7% €527,900. averted in medical costs, resulting in net between 21–25 years €626,800 Setting: The Netherlands cost savings. Sensitivity analysis showed that net (n=794), 3.3% between Methods: The authors used a health-economic cost savings remained with test costs up to 26–30 years (n=1235), €22 decision analysis model, which included potential (test price for a broad range of variation in and 1.6% in women over €19) health outcomes of C. trachomatis infection for underlying assumptions. Scenario analysis showed 30 years of age (n=1775) women, partners and infants, and premature even more cost savings with targeted screening for May not be applicable to delivery. We estimated the cost-effectiveness from women less than 30 years of age or with first the Australian context a societal perspective using recent prevalence data pregnancies only. from a population-based prospective cohort study among pregnant women in the Netherlands. We calculated the averted costs by linking health outcomes with health care costs and productivity losses. Cost-effectiveness was expressed as net costs per major outcome prevented and was estimated in base-case analysis, sensitivity, and scenario analysis.
(Rours et al 2016) study Aim: to estimate the cost-effectiveness of Chlamydia trachomatis screening during pregnancy. Setting: The Netherlands Methods: The authors used a health-economic decision analysis model, which included potential health outcomes of C. trachomatis infection for women, partners and infants, and premature delivery. We estimated the cost-effectiveness from a societal perspective using recent prevalence data from a population-based prospective cohort study among pregnant women in the Netherlands. We calculated the averted costs by linking health outcomes with health care costs and productivity losses. Cost-effectiveness was expressed as net costs per major outcome prevented and was estimated in base-case analysis, sensitivity, and scenario analysis. In the base-case analysis, the to detect 1,000 pregnant women with chlamydia were estimated at €527,900. Prevention of adverse health outcomes averted €626,800 in medical costs, resulting in net cost savings. Sensitivity analysis showed that net cost savings remained with test costs up to €22 (test price €19) for a broad range of variation in underlying assumptions. Scenario analysis showed even more cost savings with targeted screening for women less than 30 years of age or with first pregnancies only. Age-specific prevalences were 13.5% in women <21 years (n=251), 6.7% between 21–25 years (n=794), 3.3% between 26–30 years (n=1235), and 1.6% in women over 30 years of age (n=1775) May not be applicable to the Australian context
Chlamydia%20evidence%20evaluation%2015Oct18.DOCX